Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antiviral, monoclonal antibodies | 5438 | 2135632-30-1 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Odesivimab in combination with maftivimab and atoltivimab has been approved as INMAZEB for the treatment of infection caused by Zaire ebolavirus. INMAZEB is a combination of the three recombinant human IgG1kappa monoclonal antibodies that inhibit Zaire ebolavirus, each targeting the Zaire ebolavirus glycoprotein (GP). Maftivimab is a neutralizing antibody that blocks entry of the virus into susceptible cells. Odesivimab is a non-neutralizing antibody that induces antibody-dependent effector function through FcgammaRIIIa signaling when bound to its target. Odesivimab also binds to the soluble form of Zaire ebolavirus glycoprotein (sGP). Atoltivimab combines both neutralization and FcgammaRIIIa signaling activities.
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 14, 2020 | FDA | REGENERON PHARMACEUTICALS |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000998 | Antiviral Agents |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Ebola virus disease | indication | 37109004 | DOID:4325 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Low affinity immunoglobulin gamma Fc region receptor III-A | Membrane receptor | ANTIBODY BINDING | EC50 | 8.80 | DRUG LABEL | DRUG LABEL | |||
| Envelope glycoprotein | Glycoprotein | ANTIBODY BINDING | Kd | 8.08 | DRUG LABEL | DRUG LABEL |
| ID | Source |
|---|---|
| D11921 | KEGG_DRUG |
| UY9LQ8P6HW | UNII |
| C5417454 | UMLSCUI |
| CHEBI:757595 | CHEBI |
| CHEMBL4298188 | ChEMBL_ID |
| DB15900 | DRUGBANK_ID |
| 11033 | INN_ID |
| C000711951 | MESH_SUPPLEMENTAL_RECORD_UI |
| 1052218000 | SNOMEDCT_US |
| 4043572 | VANDF |
| 4043688 | VANDF |
| 018541 | NDDF |
| 2461340 | RXNORM |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Inmazeb | HUMAN PRESCRIPTION DRUG LABEL | 3 | 61755-018 | INJECTION, SOLUTION | 241.70 mg | INTRAVENOUS | BLA | 28 sections |
| Inmazeb | HUMAN PRESCRIPTION DRUG LABEL | 3 | 61755-019 | INJECTION, SOLUTION | 483.30 mg | INTRAVENOUS | BLA | 28 sections |